Arcturus Therapeutics 20-F 28 Mar 14 2013 FY Annual report (foreign) Financial data

Document_And_Entity_Informatio

Document And Entity Information	12 Months Ended
	Dec. 31, 2013
Document Information [Line Items]	'
Entity Registrant Name	'ALCOBRA LTD.
Entity Central Index Key	'0001566049
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Non-accelerated Filer
Trading Symbol	'ADHD
Entity Common Stock, Shares Outstanding	13,636,709
Document Type	'20-F
Amendment Flag	'false
Document Period End Date	31-Dec-13
Document Fiscal Period Focus	'FY
Document Fiscal Year Focus	'2013
Entity Well-known Seasoned Issuer	'No
Entity Voluntary Filers	'No
Entity Current Reporting Status	'Yes

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
CURRENT ASSETS:	'		'
Cash and cash equivalents	$22,095		$97
Short-term bank deposit	28,008		0
Receivables and prepaid expenses	115		83
Total current assets	50,218		180
LONG-TERM ASSETS:	'		'
Other long-term assets	57		3
Property and equipment, net	49		18
Total long-term assets	106		21
TOTAL ASSETS	50,324		201
CURRENT LIABILITIES:	'		'
Trade payables	47		23
Accrued expenses and other liabilities	1,589		83
Convertible Notes	0		662
Total current liabilities	1,636		768
SHAREHOLDERS' EQUITY (DEFICIENCY):	'		'
Ordinary shares of NIS 0.01 par value - 50,000,000 and 10,000,000 shares authorized at December 31, 2013 and 2012; 13,941,033 and 8,098,581 issued shares at December 31, 2013 and 2012, respectively; 13,636,709 and 7,794,256 shares outstanding at December 31, 2012, respectively	39		4
Treasury shares (304,324 ordinary shares at December 31, 2013 and 2012.)	0	[1]	0	[1]
Additional paid- in capital	67,383		7,615
Deficit accumulated during the development stage	-18,734		-8,186
Total shareholders' equity (deficiency)	48,688		-567
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)	$50,324		$201
[1]	Represents an amount less than $ 1.

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	50,000,000	10,000,000
Common stock, shares issued	13,941,033	8,098,581
Common stock, shares outstanding	13,636,709	7,794,256
Treasury Stock, Shares	304,324	304,324

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended			71 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Research and development expenses, net	$7,066	$818	$1,822	$10,834
General and administrative expenses	3,224	683	2,084	7,266
Operating loss	10,290	1,501	3,906	18,100
Financial expenses, net	197	78	23	393
Tax expenses	61	0	0	61
Net comprehensive loss	10,548	1,579	3,929	18,554
Deemed dividend	0	0	180	180
Net loss attributable to holders of ordinary shares	$10,548	$1,579	$4,109	$18,734
Net basic and diluted loss per share (in dollars per share)	($1.04)	($0.20)	($0.50)	'
Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in shares)	10,177,786	7,791,932	7,843,388	'

STATEMENTS_OF_CHANGES_IN_SHARE

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) (USD $)	Total		Common Stock [Member]		Preferred Stock [Member]		Preferred Stock [Member]		Additional Paid-in Capital [Member]		Accumulated Deficit during Development Stage [Member]
In Thousands, except Share data					Preferred Class A [Member]		Preferred Class B [Member]
Balance at Feb. 06, 2008	$0		$0		$0		$0		$0		$0
Balance (in shares) at Feb. 06, 2008	'		0		0		0		'		'
Issuance of ordinary shares at par share	3		3		0		0		0		0
Issuance of ordinary shares at par share (in shares)	'		5,752,600		0		0		'		'
Issuance of Preferred A shares, net ($0.92 per share)	657		0		0	[1]	0		657		0
Issuance of Preferred A shares, net ($0.92 per share) (in shares)	'		0		747,339		0		'		'
Issuance of Preferred shares and warrants granted to service provider	75		0		0		0		75		0
Issuance of Preferred shares and warrants granted to service provider (in shares)	'		0		81,528		0		'		'
Share based compensation related to warrants granted to consultant	28		0		0		0		28		0
Net loss	-666		0		0		0		0		-666
Balance at Dec. 31, 2008	97		3		0		0		760		-666
Balance (in shares) at Dec. 31, 2008	'		5,752,600		828,867		0		'		'
Issuance of Preferred A shares, net ($0.92 per share)	187		0		0	[1]	0		187		0
Issuance of Preferred A shares, net ($0.92 per share) (in shares)	'		0		203,818		0		'		'
Issuance of Preferred shares and warrants granted to service provider	175		0		0		0		175		0
Issuance of Preferred shares and warrants granted to service provider (in shares)	'		0		190,229		0		'		'
Conversion of Preferred shares into ordinary shares	0	[1]	0	[1]	0	[1]	0		0		0
Conversion of Preferred shares into ordinary shares (in shares)	'		461,987		-461,987		0		'		'
Net loss	-608		0		0		0		0		-608
Balance at Dec. 31, 2009	-149		3		0	[1]	0		1,122		-1,274
Balance (in shares) at Dec. 31, 2009	'		6,214,587		760,927		0		'		'
Issuance of Preferred shares and warrants granted to service provider	120		0		0		0		120		0
Issuance of Preferred shares and warrants granted to service provider (in shares)	'		0		0		55,008		'		'
Issuance of Preferred B shares and warrants, net ($2.18 per unit of 1 share and 0.25 warrant)	723		0		0		0	[1]	723		0
Issuance of Preferred B shares and warrants, net ($2.18 per unit of 1 share and 0.25 warrant) (in shares)	'		0		0		342,691		'		'
Issuance of Preferred B shares and warrants upon conversion of convertible notes	279		0		0		0		279		0
Issuance of Preferred B shares and warrants upon conversion of convertible notes (in shares)	'		0		0		128,512		'		'
Share based compensation related to options granted to consultants and employees	242		0		0		0		242		0
Exercise of options	0	[1]	0	[1]	0		0		0	[1]	0
Exercise of options (in shares)	'		288,681		0		0		'		'
Net loss	-1,224		0		0		0		0		-1,224
Balance at Dec. 31, 2010	-9		3		0	[1]	0		2,486		-2,498
Balance (in shares) at Dec. 31, 2010	'		6,503,268		760,927		526,211		'		'
Issuance of ordinary shares at par share	2,170		0	[1]	0		0		2,170		0
Issuance of ordinary shares at par share (in shares)	'		199,979		0		0		'		'
Conversion of Preferred shares into ordinary shares	0		1		0		0		-1		0
Conversion of Preferred shares into ordinary shares (in shares)	'		1,287,138		-760,927		-526,211		'		'
Share based compensation related to options granted to consultants and employees	1,553		0		0		0		1,553		0
Exercise of options	0	[1]	0	[1]	0		0		0	[1]	0
Exercise of options (in shares)	'		1,379		0		0		'		'
Deemed dividend in respect of equity restructuring	0		0		0		0		180		-180
Issuance of ordinary shares upon conversion of loan into ordinary shares net ($11.5 per share)	1,200		0	[1]	0		0		1,200		0
Issuance of ordinary shares upon conversion of loan into ordinary shares net ($11.5 per share) (in shares)	'		104,345		0		0		'		'
Net loss	-3,929		0		0		0		0		-3,929
Balance at Dec. 31, 2011	985		4		0		0		7,588		-6,607
Balance (in shares) at Dec. 31, 2011	'		8,096,109		0		0		'		'
Share based compensation related to options granted to consultants and employees	26		0		0		0		26		0
Exercise of options	1		0	[1]	0		0		1		0
Exercise of options (in shares)	'		2,471		0		0		'		'
Treasury shares	0	[1]	0	[1]	0		0		0		0
Treasury shares (in shares)	'		-304,324		0		0		'		'
Net loss	-1,579		0		0		0		0		-1,579
Balance at Dec. 31, 2012	-567		4		0		0		7,615		-8,186
Balance (in shares) at Dec. 31, 2012	'		7,794,256		0		0		'		'
Issuance of Preferred B shares and warrants upon conversion of convertible notes	980		0	[1]	0		0		980		0
Issuance of Preferred B shares and warrants upon conversion of convertible notes (in shares)	'		123,553		0		0		'		'
Share based compensation related to options granted to consultants and employees	1,540		0		0		0		1,540		0
Exercise of options	29		1		0		0		28		0
Exercise of options (in shares)	'		208,708		0		0		'		'
Issuance of shares upon cashless exercise of warrants	0	[1]	0	[1]	0		0		0		0
Issuance of shares upon cashless exercise of warrants (in shares)	'		85,192		0		0		'		'
Issuance of shares upon initial public offering ($8 per share), net of $3,080 issuance expenses	21,920		28		0		0		21,892		0
Issuance of shares upon initial public offering ($8 per share), net of $3,080 issuance expenses (in shares)	'		3,125,000		0		0		'		'
Issuance of shares upon secondary public offering ($16.5 per share),net of $2,616 issuance expenses	35,334		6		0		0		35,328		0
Issuance of shares upon secondary public offering ($16.5 per share),net of $2,616 issuance expenses (in shares)	'		2,300,000		0		0		'		'
Net loss	-10,548		0		0		0		0		-10,548
Balance at Dec. 31, 2013	$48,688		$39		$0		$0		$67,383		($18,734)
Balance (in shares) at Dec. 31, 2013	'		13,636,709		0		0		'		'
[1]	Represents an amount less than $ 1.

STATEMENTS_OF_CHANGES_IN_SHARE1

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) (Paranthetical) (USD $)	12 Months Ended		11 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2008	Dec. 31, 2009	Dec. 31, 2010	Dec. 31, 2010	Dec. 31, 2011
	IPO [Member]	Secondary Public Offering [Member]	Preferred Class A [Member]	Preferred Class A [Member]	Preferred Class B [Member]	Warrant [Member]	Common Stock [Member]
Development Stage Entities, Equity Issuance, Per Share Amount (in dollars per share)	$8	$16.50	$0.92	$0.92	$2.18	$0.25	'
Convertible Equity Issuance Price Per Share (in dollars per share)	'	'	'	'	$1.75	$0.25	$11.50
Equity Issuance Cost	$3,080	$2,616	'	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended			71 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Cash flows from operating activities	'	'	'	'
Net loss	($10,548)	($1,579)	($3,929)	($18,554)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'	'
Depreciation	8	7	6	30
Stock based compensation	1,540	26	1,553	3,759
Gain from sale of property and equipment	1	0	0	1
Decrease (increase) in receivables and prepaid expenses	-32	12	-49	-115
Decrease (increase) in other long-term assets	-54	2	0	-57
Increase (decrease) in trade payables	24	-101	95	47
Increase (decrease) in accrued expenses and other liabilities	1,505	-12	-37	1,588
Interest on convertible notes	203	62	0	324
Net cash used in operating activities	-7,353	-1,583	-2,361	-12,977
Cash flows from investing activities	'	'	'	'
Purchase of property and equipment	-39	0	-24	-79
Proceeds from (investment in) short-term bank deposit	-28,008	517	-517	-28,008
Proceeds from (investment in) restricted bank deposit	0	507	-500	0
Net cash provided by (used in) investing activities	-28,047	1,024	-1,041	-28,087
Cash flows from financing activities	'	'	'	'
Proceeds from issuance of convertible notes	115	600	0	935
Issuance of share capital upon public offering	57,254	0	0	57,254
Exercise of options	29	0	0	29
Proceeds from loan	0	0	450	1,200
Issuance of shares, net	0	1	2,170	3,741
Net cash provided by financing activities	57,398	601	2,620	63,159
Increase (decrease) in cash and cash equivalents	21,998	42	-782	22,095
Cash and cash equivalents at the beginning of the period	97	55	837	0
Cash and cash equivalents at the end of the period	22,095	97	55	22,095
Supplemental disclosure of non-cash investing and financing activities:	'	'	'	'
Issuance of ordinary shares upon conversion of convertible notes	980	0	0	980
Issuance of ordinary shares upon conversion of loans	$0	$0	$1,200	$1,200

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	NOTE 1:-	GENERAL
		a.	Alcobra Ltd. was incorporated in Israel and commenced its operation on February 7, 2008. During July 2013, a wholly- owned subsidiary was established in the state of Delaware named Alcobra Inc. (the "Subsidiary"). Alcobra Ltd. and its Subsidiary (collectively "the Company") are an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, to treat Attention Deficit Hyperactivity Disorder, ("ADHD"), and other potential cognitive dysfunctions including Fragile X. The Company's objective is to conduct additional clinical trials for its drug called MDX (the "Drug") and, if those trials are successful, seek marketing approval from the U.S. Food and Drug Administration (the "FDA") and other worldwide regulatory bodies.
		b.	The Company has not generated revenue from the sale of any product, and does not expect to generate significant revenue unless and until obtaining of marketing approval and commercializing the MDX. Accordingly, the Company is considered to be in the development stage as defined in ASC 915, "Development stage entities". The Company has incurred losses in the amount of $ 10,548 thousand during the year ended December 31, 2013. The Company has an accumulated deficit in the total amount of $ 18,734 as of December 31, 2013 and as of that date the accumulated negative cash flow from operating activity is in the amount of $ 12,977.
	The Company believes that its existing cash and cash equivalents and short term bank deposits should be sufficient to meet its operating and capital requirements through 2016.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 2:-	SIGNIFICANT ACCOUNTING POLICIES
	The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP").
		a.	Use of estimates:
	The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
		b.	Financial statements in U.S. dollars:
	The Company finances its operations in U.S. dollars. The majority of the Company's operations are currently conducted in Israel, a significant part of the Company's expenses are denominated and determined in U.S. dollars. The Company's management believes that the dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, the functional and reporting currency of the Company is the U.S. dollar.
	The Company's transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been remeasured to U.S. dollars in accordance with ASC 830, "Foreign Currency Matters", of the Financial Accounting Standards Board ("FASB"). All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate.
		c.	Principles of consolidation:
	The consolidated financial statements include the accounts of Alcobra Ltd. and its Subsidiary. Intercompany transactions and balances have been eliminated upon consolidation.
		d.	Cash equivalents:
	Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.
		e.	Short-term bank deposit
	Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short–term bank deposits are presented at their cost, including accrued interest, which approximates fair value. As of December 31, 2013, the Company's bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.42%.
		f.	Property and equipment, net:
	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:
			%
	Computers and electronic equipment		15-33
	Office furniture and equipment		6
	Clinical and medical equipment		15-33
	Leasehold improvement		The shorter of term of the lease or the
			useful life of the asset
	The Company's property and equipment are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment," whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2013 and 2012, no impairment losses have been identified.
		g.	Long-term deposits:
	Long-term deposits include long-term deposits for office lease prepaid deposit and motor vehicles under operating leases, presented at their cost.
		h.	Research and development expenses:
	Research and development expenses are expensed as incurred. Those expenses include payments to third party clinical consultants, expenses related to conducting clinical and pre-clinical trials, salaries and related personnel expenses, travel expenses, and share based compensation expenses to research and development employees. During 2013, 2012 and 2011, no grants were received.
		i.	Severance pay:
	The Company's liability for its Israeli employees regarding severance pay is pursuant to Section 14 of the Israeli severance pay law ("Section 14"). All the Israeli employees are included under this section, and entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee's name with insurance companies. Payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the balance sheet as the severance pay risks have been irrevocably transferred to the severance funds.
	Severance pay expense for the years ended December 31, 2013, 2012 and 2011, amounted to $ 26, $ 18 and $ 14, respectively.
		j.	Income taxes:
	The Company accounts for income taxes in accordance with ASC 740, "Income Taxes" ("ASC 740"). This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.
	The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.
	The Company believes that its tax positions are all highly certain of being upheld upon examination. As such, as of December 31, 2013 and 2012 the Company has not recorded a liability for uncertain tax positions.
		k.	Concentrations of credit risk:
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and short term bank deposit.
	Cash and cash equivalents and short term bank deposit are invested in major banks in Israel and the deposits in the U.S. may be in excess of insured limits and are not insured in other jurisdictions. Generally, these deposits may be redeemed upon demand and therefore bear minimal risk.
	The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
		l.	Fair value of financial instruments:
	The Company has no financial instruments that are measured at fair value.
	The carrying amounts of cash and cash equivalents, short term bank deposits, accounts receivable and accounts payable, approximate their fair value due to the short-term maturities of such instruments.
		m.	Basic and diluted net loss per share:
	Basic net loss per share is computed based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of ordinary shares outstanding during each year plus dilutive potential equivalent ordinary shares considered outstanding during the year, in accordance with ASC 260, "Earnings per Share."
	The total weighted average number of shares related to the outstanding options and warrants excluded from the calculations of diluted net loss per share, since they would have an anti-dilutive effect, was 873,031, 537,690 and 561,198 for the years ended December 31, 2013, 2012 and 2011, respectively.
		n.	Accounting for stock-based compensation:
	The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation"("ASC 718") that requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the option award is recognized as an expense over the requisite service periods in the Company's statements of operations based on the accelerated method.
	The Company selected the Black-Scholes-Merton ("Black-Scholes") option-pricing model as the fair value method for of its stock-options awards. The option-pricing model requires a number of assumptions as noted below:
	Expected dividend yield - The expected dividend yield assumption is based on the Company's historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.
	Volatility - Since the Company's shares started trading in NASDAQ in May 2013, sufficient quoted prices of the Company's share are unavailable. Due to insufficient historical data for the Company, the expected volatility determination was based on similar companies' stock volatility.
	Risk free interest rate - The risk free interest rate is based on the yield of U.S Treasury bonds with equivalent terms.
	Expected term - ASC 718 provides the factors to consider when estimating the expected term of an option: An option's expected term must at least include the vesting period and the employees' historical exercise and post-vesting employment termination behavior for similar grants. It also determines that if the amount of past exercise data is limited, that data may not represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior. In that circumstance, it may be appropriate to consider external data or the SEC staff's "simplified" method for the expected term. Accordingly, The Company used the "simplified" method, meaning the expected life can be set as the average of the vesting period for each vested tranche of options and the contractual term for those options.

RECEIVABLES_AND_PREPAID_EXPENS

RECEIVABLES AND PREPAID EXPENSES	12 Months Ended
	Dec. 31, 2013
Receivables and Prepaid Expenses [Abstract]	'
Receivables and Prepaid Expenses [Text Block]	'
	NOTE 3:-	RECEIVABLES AND PREPAID EXPENSES
			December 31,
			2013		2012
	Government authorities		$	46	$	10
	Prepaid expenses			18		66
	Other current assets			51		7
			$	115	$	83

PROPERTY_AND_EQUIPMENT_NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 4:	PROPERTY AND EQUIPMENT, NET
			December 31,
			2013		2012
	Cost:
	Computers and electronic equipment		$	32	$	19
	Office furniture and equipment			23		7
	Leasehold improvement			5		-
	Clinical and medical equipment			19		14
				79		40
	Accumulated depreciation:
	Computers and electronic equipment			17		13
	Office furniture and equipment			2		1
	Leasehold improvement			1		-
	Clinical and medical equipment			10		8
				30		22
	Depreciated cost		$	49	$	18
	Depreciation expenses for the years ended December 31, 2013, 2012 and 2011, were $ 8, $ 7 and $ 6, respectively.

ACCRUED_EXPENSES_AND_OTHER_LIA

ACCRUED EXPENSES AND OTHER LIABILITIES	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	NOTE 5:-	ACCRUED EXPENSES AND OTHER LIABILITIES
			December 31,
			2013		2012
	Employees and payroll accruals		$	264	$	31
	Accrued expenses			1,264		52
	Government authorities			61		-
			$	1,589	$	83

CONVERTIBLE_NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	NOTE 6:-	CONVERTIBLE NOTES
	During 2012 and 2013, the Company issued convertible promissory notes to certain investors for a total amount of $  715. The convertible notes bore an annual interest rate of 6%.
	In connection with the Company's Initial Public Offering, ("IPO"),  in May 2013, according to the terms of the convertible notes, in May 2013 the notes were automatically converted into 123,553 ordinary shares of the Company. Upon conversion of the convertible notes, the entire redemption amount was derecognized against additional paid in capital in the amount of $ 980. The financial expenses for the years ended December 31, 2013 and 2012, amounted to $ 203 and $52, respectively.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 7:-	INCOME TAXES
		a.	Tax laws applicable to Alcobra Ltd. and the Subsidiary:
		1	Alcobra Ltd. is taxed under the Israeli income tax law.
		2	The Subsidiary is taxed under U.S. tax law.
		b.	Tax rates applicable to the Company and the Subsidiary:
		1	Alcobra Ltd:
	Taxable income of Israeli companies is subject to tax at the rate of 25% in 2012 and in 2013 and a rate of 26.5% commencing January 1, 2014.
		2	The Subsidiary:
	The federal  tax rates applicable to the Company whose place of incorporation is within the U.S. are corporate (progressive) tax at the rate of up to 35%, excluding state tax, which rates depend on the state in which the Company conducts its business.
		c.	Net operating losses carry forward:
	Alcobra Ltd. has accumulated losses for tax purposes in Israel as of December 31, 2013 in the amount of approximately $  10,241 which may be carried forward and offset against taxable income in the future for an indefinite period.
		d.	Deferred income taxes:
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows:
			December 31,
			2013		2012
	Operating loss carry forward		$	2,713	$	1,153
	Reserves and allowances			1,358		308
	Deferred tax assets before valuation allowance			4,071		1,461
	Valuation allowance			-4,071		-1,461
	Net deferred tax assets		$	-	$	-
	All deferred taxes are domestic. Management currently believes that since the Company has a history of losses it is more likely than not that the deferred tax regarding the loss carry forward and other temporary differences will not be realized in the foreseeable future.
		e.	No liability for uncertain tax positions was recorded as a result of implementation of ASC 740.
		f.	The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowances in respect of deferred taxes due to the uncertainty of the realization of such deferred taxes.
		g.	Net comprehensive loss (income) before taxes on income is comprised as follows:
			December 31,
			2013		2012		2011
	Domestic (Israel)		$	10,505	$	1,579	$	3,929
	Foreign (U.S)			-18		-		-
			$	10,487	$	1,579	$	3,929
		h.	Taxes on income relate solely to the foreign Subsidiary.

CONTINGENT_LIABILITIES_AND_COM

CONTINGENT LIABILITIES AND COMMITMENTS	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 8:-	CONTINGENT LIABILITIES AND COMMITMENTS
		a.	The Company is engaged in two operating lease agreements for its facilities. The rent expenses for the years ended December 31, 2013, 2012 and 2011, amounted to $  50, $ 44 and $ 61, respectively. Future minimum payments under the leases are as follows:
	Year ended December 31,		Total
	2014		$	122
	2015			102
	2016			73
			$	297
		b.	On June 2013 the Company entered into a new operating lease agreement for its vehicles until 2016. The rent expenses for the year ended December 31, 2013, 2012 and 2011, amounted to $  51, $ 18 and $ 29, respectively. Future minimum payments under the lease are as follows:
	Year ended December 31,		Total
	2014		$	48
	2015			41
	2016			22
			$	111
		c.	Royalty bearing Government grants:
	The Company partially financed its research and development expenditures under programs sponsored by the Office of Chief Scientist ("OCS") for the support of certain research and development activities conducted in Israel.
	In connection with its research and development, the Company received $  106 of participation payments from the OCS through December 31, 2013. In return for the OCS's participation, the Company is committed to pay royalties at a rate of 3%-5% of sales of the developed product linked to U.S dollars, up to 100% of the amount of grants received (100% plus interest at LIBOR). The Company's total commitment for royalties payable with respect to future sales, based on OCS participations received or accrued, net of royalties paid or accrued, totaled approximately $  115 as of December 31, 2013. In addition, the OCS may impose certain conditions on any arrangement under which it permits the Company to transfer technology or development out of Israel.

SHAREHOLDERS_EQUITY_DEFICIENCY

SHAREHOLDERS' EQUITY (DEFICIENCY)	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Stockholders Equity Note Disclosure [Text Block]	'
	NOTE 9:-	SHAREHOLDERS' EQUITY (DEFICIENCY)
		a.	General:
		1	All ordinary shares, options, warrants, per share data, exercise price and convertible notes conversion ratio included in these financial statements for all periods presented have been retroactively adjusted to reflect the issuance on May 19, 2013 of 4.87-to-one bonus shares (equivalent to a 5.87-for-1 stock split).
		2	During March 2013, the Company's general meeting resolved to increase the Company's authorized shares from 10,000,000 to 50,000,000 ordinary shares.
		b.	Share capital:
			The ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share in the distribution of dividends, if any declared by the Company.
		c.	Issuances of share:
		1	During May 2013, the Company completed an IPO and listed its ordinary shares on the "NASDAQ Capital Market" and issued 3,125,000 ordinary shares in consideration of approximately $21,920, net.
	Following the IPO and according to the terms of the convertible notes, the notes were automatically converted into 123,553 ordinary shares of the Company. In addition, 120,255 warrants were exercised into 85,192 ordinary shares of the Company, using the cashless exercise method.
		2	During October 2013, the Company completed a secondary public offering in the "NASDAQ Capital Market" and issued 2,300,000 ordinary shares in consideration of approximately $35,334, net.
		d.	2010 incentive option plan:
	In February 2010, the Company authorized through its 2010 incentive option plan (the "2010 Plan") the grant of options to officers, directors, advisors, management and other key employees. The Company reserved for grants of options up to 1,693,047 of the Company's ordinary shares. The options granted have generally four year vesting terms and expire ten years after the grant date. As of December 31, 2013, 372,725 options were still available for future grants under the Plan.
	A summary of the Company's options activity (for employees and directors) under the 2010 Plan is as follows:
			Year ended December 31,
			2013					2012
					Weighted					Weighted
					average					average
					exercise			Number of		exercise
			Number of options		price			options		price
	Outstanding at beginning of year		461,118		$	0.2		465,520		$	0.21
	Granted *)		552,890		$	9.87		-			-
	Exercised		-208,708		$	0.14		-2,471		$	0.33
	Forfeited		-					-1,931		$	0.33
	Outstanding at end of year		805,300		$	6.86		461,118		$	0.2
	Vested and expected to vest		805,300		$	6.86		461,118		$	0.2
	Options exercisable at the end of the period		308,909		$	0.33		366,464		$	0.22
	As of December 31, 2013, the weighted-average remaining contractual term of the outstanding and exercisable options is 8.19 and 6.37 years; the aggregated intrinsic value of outstanding and exercisable options is $ 8,957 and $ 5,459, respectively. As of December 31, 2013, the unrecognized compensation cost is $ 1,921 and $ 603 to be recognized in 2014 and 2015, respectively.
	*) Including 22,388 and 102,275 options to purchase ordinary shares granted in May and December 2013 to a director and an employee, respectively. The exercise price is $ 8 and $ 17.6, respectively. The vesting of the options is subject to certain performance conditions. As of December 31, 2013, the performance conditions are probable and the Company recorded share based expenses in the amount of $ 109.
		e.	Options granted to consultants:
	The Company granted options to certain service providers and accounted for these options in accordance with ASC 505-50, "Equity-Based payment to non-employees".
	The outstanding options granted to the Company's consultants are as follows:
			Number of			Exercise
	Grant date		options			price		Expiration date
	2-Apr-08		58,700			0.0005		2-Apr-18
	28-Feb-10		8,805			2.184		28-Feb-20
	13-Feb-11		1,174			0.0005		13-Feb-21
	17-Feb-11		3,804			0.0005		17-Feb-21
			72,483	*)
	*) All options were fully vested on grant date.
		f.	Warrants granted to underwriters:
	The outstanding options granted to the underwriters  for the IPO are as follows:
			Number of		Exercise
	Grant date		options		price		Expiration date
	28-May-13		52,083		12		28-May-15
	28-May-13		52,083		16		28-Nov-15
	28-May-13		52,084		20		28-May-16
			156,250
		g.	Share-based payment:
	The share-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table:
												Period from
												February 7,
												2008 (dtae of
			Year ended									inception) to
			December 31,									December 31,
			2013			2012			2011			2013
	Research and development, net		$	430		$	*) -		$	18		$	913
	General and administrative expenses			1,110			26			1,535			2,846
			$	1,540		$	26		$	1,553		$	3,759
		*)	Represents an amount less than $ 1.

RELATED_PARTY_BALANCES_AND_TRA

RELATED PARTY BALANCES AND TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 10:-	RELATED PARTY BALANCES AND TRANSACTIONS
	Balances with related parties:
			December 31,
			2013		2012
	Convertible notes (e)		$	-	$	610
	Other accounts payable (c) (d)		$	47	$	21
	Related parties' expenses:
			Year ended
			December 31,
			2013		2012		2011
	Amounts charged to: *)
	Research and development expenses (b) (d)		$	341	$	-	$	-
	General and administrative expense (a) (b) (c) (d)		$	1,266	$	401	$	1,786
	Financial expense (e)		$	-	$	60	$	-
		*)	Including share based compensation expenses for the years ended December 31, 2013, 2012 and 2011, in the amounts of $  841, $ 26 and $ 1,394, respectively.
	a. On March 1, 2008, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, as a contractor to render management, finance and operation services. The Company pays the consultant an amount of $ 7 per month. During May 2013, the monthly fee was increased to an amount of $ 12. The amendment was effective upon consummation of the IPO in May 2013. In June 2013, and in connection to the consummation of the IPO, the Company granted the consultant a bonus in the amount of $50. (see also Note 12 (a)).
		b.	The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the company renders the Company with office services and office lease for a monthly fee in the amount of approximately $ 4 since June 1, 2010. Each party may terminate the agreement with 30-days' notice. The agreement was terminated in September 2013.
		c.	An agreement was signed on June 2, 2011 between the Company and one its shareholders, as a contractor to render services related to pre-clinical, clinical, regulatory and intellectual property issues, for an amount of approximately $ 3 per month. During May 2013, the monthly fee was increased to an amount of $ 5. The amendment was effective upon consummation of the IPO in May 2013.
		d.	Under the employment agreement, dated March 4, 2010, with the Company's Chief Executive Officer and Director, and following a salary increase approved April 14, 2011, the CEO was entitled to a gross monthly salary of $  14. During January 2013, the Company increased the monthly salary to an amount of $ 15 which became effective upon the Company's IPO. In June 2013, the Company granted the CEO a bonus in the amount of $ 75 in connection with the consummation of the IPO and in August 2013, the Company increased the bonus amount in $ 125, to a total of $ 200. (see also Note 12 (a)).
		e.	One of the Company's shareholders invested as part of the Company's issuance of the Convertible notes.

FINANCIAL_EXPENSES_NET

FINANCIAL EXPENSES, NET	12 Months Ended
	Dec. 31, 2013
Interest Income (Expense), Net [Abstract]	'
Interest Income and Interest Expense Disclosure [Text Block]	'
	NOTE 11:-	FINANCIAL EXPENSES, NET
									Period from
									February 7,
									2008 (date of
			Year ended						inception) to
			December 31,						December 31,
			2013		2012		2011		2013
	Financial expenses:
	Interest expense		$	-	$	3	$	3	$	23
	Exchange rate			7		15		41		99
	Bank fees			9		-		-		9
	Interest on convertible notes			203		62		-		310
				219		80		44		441
	Financial income:
	Interest income			22		2		21		48
				22		2		21		48
			$	197	$	78	$	23	$	393

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 12:-	SUBSEQUENT EVENTS
		a.	During February 2014, the Company's shareholders resolved to grant the Company's CFO and CEO bonuses in the amount of $ 200 and $ 200, respectively. (see also Note 10 (a) and (d)).  In addition, the shareholders had approved a grant of 150,000 options to the CEO.
		b.	During February and March  2014, the Company's Board of Directors resolved to grant an aggregate number of 155,000 options to two employees.
		c.	During March 2014, the Company's board of directors resolved to   increase the number of options available for future grant under the option plan by 172,725.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
		a.	Use of estimates:
	The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Financial Statements [Policy Text Block]	'
		b.	Financial statements in U.S. dollars:
	The Company finances its operations in U.S. dollars. The majority of the Company's operations are currently conducted in Israel, a significant part of the Company's expenses are denominated and determined in U.S. dollars. The Company's management believes that the dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, the functional and reporting currency of the Company is the U.S. dollar.
	The Company's transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been remeasured to U.S. dollars in accordance with ASC 830, "Foreign Currency Matters", of the Financial Accounting Standards Board ("FASB"). All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate.
Consolidation, Policy [Policy Text Block]	'
		c.	Principles of consolidation:
	The consolidated financial statements include the accounts of Alcobra Ltd. and its Subsidiary. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
		d.	Cash equivalents:
	Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.
Short Term Deposit [Policy Text Block]	'
		e.	Short-term bank deposit
	Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short–term bank deposits are presented at their cost, including accrued interest, which approximates fair value. As of December 31, 2013, the Company's bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.42%.
Property, Plant and Equipment, Policy [Policy Text Block]	'
		f.	Property and equipment, net:
	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:
			%
	Computers and electronic equipment		15-33
	Office furniture and equipment		6
	Clinical and medical equipment		15-33
	Leasehold improvement		The shorter of term of the lease or the
			useful life of the asset
	The Company's property and equipment are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment," whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2013 and 2012, no impairment losses have been identified.
Long Term Deposit [Policy Text Block]	'
		g.	Long-term deposits:
	Long-term deposits include long-term deposits for office lease prepaid deposit and motor vehicles under operating leases, presented at their cost.
Research and Development Expense, Policy [Policy Text Block]	'
		h.	Research and development expenses:
	Research and development expenses are expensed as incurred. Those expenses include payments to third party clinical consultants, expenses related to conducting clinical and pre-clinical trials, salaries and related personnel expenses, travel expenses, and share based compensation expenses to research and development employees. During 2013, 2012 and 2011, no grants were received.
Severance Pay [Policy Text Block]	'
		i.	Severance pay:
	The Company's liability for its Israeli employees regarding severance pay is pursuant to Section 14 of the Israeli severance pay law ("Section 14"). All the Israeli employees are included under this section, and entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee's name with insurance companies. Payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the balance sheet as the severance pay risks have been irrevocably transferred to the severance funds.
	Severance pay expense for the years ended December 31, 2013, 2012 and 2011, amounted to $ 26, $ 18 and $ 14, respectively.
Income Tax, Policy [Policy Text Block]	'
		j.	Income taxes:
	The Company accounts for income taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.
	The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.
	The Company believes that its tax positions are all highly certain of being upheld upon examination. As such, as of December 31, 2013 and 2012 the Company has not recorded a liability for uncertain tax positions.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
		k.	Concentrations of credit risk:
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and short term bank deposit.
	Cash and cash equivalents and short term bank deposit are invested in major banks in Israel and the deposits in the U.S. may be in excess of insured limits and are not insured in other jurisdictions. Generally, these deposits may be redeemed upon demand and therefore bear minimal risk.
	The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
		l.	Fair value of financial instruments:
	The Company has no financial instruments that are measured at fair value.
	The carrying amounts of cash and cash equivalents, short term bank deposits, accounts receivable and accounts payable, approximate their fair value due to the short-term maturities of such instruments.
Earnings Per Share, Policy [Policy Text Block]	'
		m.	Basic and diluted net loss per share:
	Basic net loss per share is computed based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of ordinary shares outstanding during each year plus dilutive potential equivalent ordinary shares considered outstanding during the year, in accordance with ASC 260, "Earnings per Share."
	The total weighted average number of shares related to the outstanding options and warrants excluded from the calculations of diluted net loss per share, since they would have an anti-dilutive effect, was 873,031, 537,690 and 561,198 for the years ended December 31, 2013, 2012 and 2011, respectively.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
		n.	Accounting for stock-based compensation:
	The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation"("ASC 718") that requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the option award is recognized as an expense over the requisite service periods in the Company's statements of operations based on the accelerated method.
	The Company selected the Black-Scholes-Merton ("Black-Scholes") option-pricing model as the fair value method for of its stock-options awards. The option-pricing model requires a number of assumptions as noted below:
	Expected dividend yield - The expected dividend yield assumption is based on the Company's historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.
	Volatility - Since the Company's shares started trading in NASDAQ in May 2013, sufficient quoted prices of the Company's share are unavailable. Due to insufficient historical data for the Company, the expected volatility determination was based on similar companies' stock volatility.
	Risk free interest rate - The risk free interest rate is based on the yield of U.S Treasury bonds with equivalent terms.
	Expected term - ASC 718 provides the factors to consider when estimating the expected term of an option: An option's expected term must at least include the vesting period and the employees' historical exercise and post-vesting employment termination behavior for similar grants. It also determines that if the amount of past exercise data is limited, that data may not represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior. In that circumstance, it may be appropriate to consider external data or the SEC staff's "simplified" method for the expected term. Accordingly, The Company used the "simplified" method, meaning the expected life can be set as the average of the vesting period for each vested tranche of options and the contractual term for those options.

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Property and Equipment, Schedule of Depreciation Rate [Table Text Block]	'
	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:
		%
	Computers and electronic equipment	15-33
	Office furniture and equipment	6
	Clinical and medical equipment	15-33
	Leasehold improvement	The shorter of term of the lease or the
		useful life of the asset

RECEIVABLES_AND_PREPAID_EXPENS1

RECEIVABLES AND PREPAID EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables and Prepaid Expenses [Abstract]	'
Schedule of Receivables and Prepaid Expenses, Current [Table Text Block]	'
		December 31,
		2013		2012
	Government authorities	$	46	$	10
	Prepaid expenses		18		66
	Other current assets		51		7
		$	115	$	83

PROPERTY_AND_EQUIPMENT_NET_Tab

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of Rate of Calculating Depreciation for Property Plant and Equipment [Table Text Block]	'
		December 31,
		2013		2012
	Cost:
	Computers and electronic equipment	$	32	$	19
	Office furniture and equipment		23		7
	Leasehold improvement		5		-
	Clinical and medical equipment		19		14
			79		40
	Accumulated depreciation:
	Computers and electronic equipment		17		13
	Office furniture and equipment		2		1
	Leasehold improvement		1		-
	Clinical and medical equipment		10		8
			30		22
	Depreciated cost	$	49	$	18

ACCRUED_EXPENSES_AND_OTHER_LIA1

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		December 31,
		2013		2012
	Employees and payroll accruals	$	264	$	31
	Accrued expenses		1,264		52
	Government authorities		61		-
		$	1,589	$	83

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Significant components of the Company's deferred tax assets are as follows:
		December 31,
		2013		2012
	Operating loss carry forward	$	2,713	$	1,153
	Reserves and allowances		1,358		308
	Deferred tax assets before valuation allowance		4,071		1,461
	Valuation allowance		-4,071		-1,461
	Net deferred tax assets	$	-	$	-
Comprehensive Income (Loss) [Table Text Block]	'
	Net comprehensive loss (income) before taxes on income is comprised as follows:
		December 31,
		2013		2012		2011
	Domestic (Israel)	$	10,505	$	1,579	$	3,929
	Foreign (U.S)		-18		-		-
		$	10,487	$	1,579	$	3,929

CONTINGENT_LIABILITIES_AND_COM1

CONTINGENT LIABILITIES AND COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum payments under the leases are as follows:
	Year ended December 31,	Total
	2014	$	122
	2015		102
	2016		73
		$	297
	Future minimum payments under the lease are as follows:
	Year ended December 31,	Total
	2014	$	48
	2015		41
	2016		22
		$	111

SHAREHOLDERS_EQUITY_DEFICIENCY1

SHAREHOLDERS' EQUITY (DEFICIENCY) (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the Company's options activity (for employees and directors) under the 2010 Plan is as follows:
			Year ended December 31,
			2013					2012
					Weighted					Weighted
					average					average
					exercise			Number of		exercise
			Number of options		price			options		price
	Outstanding at beginning of year		461,118		$	0.2		465,520		$	0.21
	Granted *)		552,890		$	9.87		-			-
	Exercised		-208,708		$	0.14		-2,471		$	0.33
	Forfeited		-					-1,931		$	0.33
	Outstanding at end of year		805,300		$	6.86		461,118		$	0.2
	Vested and expected to vest		805,300		$	6.86		461,118		$	0.2
	Options exercisable at the end of the period		308,909		$	0.33		366,464		$	0.22
	*) Including 22,388 and 102,275 options to purchase ordinary shares granted in May and December 2013 to a director and an employee, respectively. The exercise price is $ 8 and $ 17.6, respectively. The vesting of the options is subject to certain performance conditions. As of December 31, 2013, the performance conditions are probable and the Company recorded share based expenses in the amount of $ 109.
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	The outstanding options granted to the Company's consultants are as follows:
			Number of			Exercise
	Grant date		options			price		Expiration date
	2-Apr-08		58,700			0.0005		2-Apr-18
	28-Feb-10		8,805			2.184		28-Feb-20
	13-Feb-11		1,174			0.0005		13-Feb-21
	17-Feb-11		3,804			0.0005		17-Feb-21
			72,483	*)
	*) All options were fully vested on grant date.
Schedule of Other Share-based Compensation, Activity [Table Text Block]	'
	The outstanding options granted to the underwriters  for the IPO are as follows:
			Number of		Exercise
	Grant date		options		price		Expiration date
	28-May-13		52,083		12		28-May-15
	28-May-13		52,083		16		28-Nov-15
	28-May-13		52,084		20		28-May-16
			156,250
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	'
	The share-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table:
												Period from
												February 7,
												2008 (dtae of
			Year ended									inception) to
			December 31,									December 31,
			2013			2012			2011			2013
	Research and development, net		$	430		$	*) -		$	18		$	913
	General and administrative expenses			1,110			26			1,535			2,846
			$	1,540		$	26		$	1,553		$	3,759
		*)	Represents an amount less than $ 1.

RELATED_PARTY_BALANCES_AND_TRA1

RELATED PARTY BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Balances with related parties:
			December 31,
			2013		2012
	Convertible notes (e)		$	-	$	610
	Other accounts payable (c) (d)		$	47	$	21
	Related parties' expenses:
			Year ended
			December 31,
			2013		2012		2011
	Amounts charged to: *)
	Research and development expenses (b) (d)		$	341	$	-	$	-
	General and administrative expense (a) (b) (c) (d)		$	1,266	$	401	$	1,786
	Financial expense (e)		$	-	$	60	$	-
		*)	Including share based compensation expenses for the years ended December 31, 2013, 2012 and 2011, in the amounts of $  841, $ 26 and $ 1,394, respectively.
	a. On March 1, 2008, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, as a contractor to render management, finance and operation services. The Company pays the consultant an amount of $ 7 per month. During May 2013, the monthly fee was increased to an amount of $ 12. The amendment was effective upon consummation of the IPO in May 2013. In June 2013, and in connection to the consummation of the IPO, the Company granted the consultant a bonus in the amount of $50. (see also Note 12 (a)).
		b.	The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the company renders the Company with office services and office lease for a monthly fee in the amount of approximately $ 4 since June 1, 2010. Each party may terminate the agreement with 30-days' notice. The agreement was terminated in September 2013.
		c.	An agreement was signed on June 2, 2011 between the Company and one its shareholders, as a contractor to render services related to pre-clinical, clinical, regulatory and intellectual property issues, for an amount of approximately $ 3 per month. During May 2013, the monthly fee was increased to an amount of $ 5. The amendment was effective upon consummation of the IPO in May 2013.
		d.	Under the employment agreement, dated March 4, 2010, with the Company's Chief Executive Officer and Director, and following a salary increase approved April 14, 2011, the CEO was entitled to a gross monthly salary of $  14. During January 2013, the Company increased the monthly salary to an amount of $ 15 which became effective upon the Company's IPO. In June 2013, the Company granted the CEO a bonus in the amount of $ 75 in connection with the consummation of the IPO and in August 2013, the Company increased the bonus amount in $ 125, to a total of $ 200. (see also Note 12 (a)).
		e.	One of the Company's shareholders invested as part of the Company's issuance of the Convertible notes.

FINANCIAL_EXPENSES_NET_Tables

FINANCIAL EXPENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2013
Interest Income (Expense), Net [Abstract]	'
Interest Income and Interest Expense Disclosure [Table Text Block]	'
								Period from
								February 7,
								2008 (date of
		Year ended						inception) to
		December 31,						December 31,
		2013		2012		2011		2013
	Financial expenses:
	Interest expense	$	-	$	3	$	3	$	23
	Exchange rate		7		15		41		99
	Bank fees		9		-		-		9
	Interest on convertible notes		203		62		-		310
			219		80		44		441
	Financial income:
	Interest income		22		2		21		48
			22		2		21		48
		$	197	$	78	$	23	$	393

GENERAL_Details_Textual

GENERAL (Details Textual) (USD $)	11 Months Ended	12 Months Ended					71 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2008	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2013
Organization Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'	'	'	'	'	'	'
Net comprehensive loss	$666	$10,548	$1,579	$3,929	$1,224	$608	$18,554
Deficit accumulated during the development stage	'	-18,734	-8,186	'	'	'	-18,734
Net Cash Provided by (Used in) Operating Activities	'	($7,353)	($1,583)	($2,361)	'	'	($12,977)

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2013
Computer Equipment [Member] | Minimum [Member]	'
Property and Equipment Schedule of Depreciation Rate [Line Items]	'
Property, Plant and Equipment, Salvage Value, Percentage	15.00%
Computer Equipment [Member] | Maximum [Member]	'
Property and Equipment Schedule of Depreciation Rate [Line Items]	'
Property, Plant and Equipment, Salvage Value, Percentage	33.00%
Furniture and Fixtures [Member]	'
Property and Equipment Schedule of Depreciation Rate [Line Items]	'
Property, Plant and Equipment, Salvage Value, Percentage	6.00%
Clinical and Medical Equipment [Member] | Minimum [Member]	'
Property and Equipment Schedule of Depreciation Rate [Line Items]	'
Property, Plant and Equipment, Salvage Value, Percentage	15.00%
Clinical and Medical Equipment [Member] | Maximum [Member]	'
Property and Equipment Schedule of Depreciation Rate [Line Items]	'
Property, Plant and Equipment, Salvage Value, Percentage	33.00%
Leasehold Improvements [Member]	'
Property and Equipment Schedule of Depreciation Rate [Line Items]	'
Property, Plant and Equipment, Estimated Useful Lives	'The shorter of term of the lease or the useful life of the asset

SIGNIFICANT_ACCOUNTING_POLICIE4

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Line Items]	'	'	'
Short Term Deposit Weighted Average Interest Rate	0.42%	'	'
Percentage of Severance Pay	8.33%	'	'
Severance Costs	$26	$18	$14
Effective Income Tax Rate Reconciliation, Tax Settlement, Percent, Total	50.00%	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	873,031	537,690	561,198

RECEIVABLES_AND_PREPAID_EXPENS2

RECEIVABLES AND PREPAID EXPENSES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Receivables And Prepaid Expenses [Line Items]	'	'
Government authorities	$46	$10
Prepaid expenses	18	66
Other current assets	51	7
Receivables And Prepaid Expenses Current	$115	$83

PROPERTY_AND_EQUIPMENT_NET_Det

PROPERTY AND EQUIPMENT, NET (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Rate Of Calculating Depreciation For Property Plant And Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$79	$40
Accumulated Depreciation, Property, Plant, and Equipment	30	22
Depreciated cost	49	18
Computer Equipment [Member]	'	'
Rate Of Calculating Depreciation For Property Plant And Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	32	19
Accumulated Depreciation, Property, Plant, and Equipment	17	13
Furniture and Fixtures [Member]	'	'
Rate Of Calculating Depreciation For Property Plant And Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	23	7
Accumulated Depreciation, Property, Plant, and Equipment	2	1
Leasehold improvements [Member]	'	'
Rate Of Calculating Depreciation For Property Plant And Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	5	0
Accumulated Depreciation, Property, Plant, and Equipment	1	0
Clinical and Medical Equipment [Member]	'	'
Rate Of Calculating Depreciation For Property Plant And Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	19	14
Accumulated Depreciation, Property, Plant, and Equipment	$10	$8

PROPERTY_AND_EQUIPMENT_NET_Det1

PROPERTY AND EQUIPMENT, NET (Details Textual) (USD $)	12 Months Ended			71 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation	$8	$7	$6	$30

ACCRUED_EXPENSES_AND_OTHER_LIA2

ACCRUED EXPENSES AND OTHER LIABILITIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts Payable and Accrued Liabilities [Line Items]	'	'
Employees and payroll accruals	$264	$31
Accrued expenses	1,264	52
Government authorities	61	0
Accounts Payable, Other, Current	$1,589	$83

CONVERTIBLE_NOTES_Details_Text

CONVERTIBLE NOTES (Details Textual) (USD $)	12 Months Ended			71 Months Ended	12 Months Ended		1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	31-May-13
					Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	IPO [Member]
Proceeds from Convertible Debt	$115	$600	$0	$935	$715	$715	'
Debt Instrument, Interest Rate During Period	6.00%	'	'	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	'	'	'	'	123,553
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	'	'	'	'	'	'	980
Interest Expense, Debt	$203	$52	'	'	'	'	'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Operating loss carry forward	$2,713	$1,153
Reserves and allowances	1,358	308
Net deferred tax asset before valuation allowance	4,071	1,461
Valuation allowance	-4,071	-1,461
Net deferred tax assets	$0	$0

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other Comprehensive Income (Loss), Tax [Abstract]	'	'	'
Net comprehensive loss (income) before taxes	$10,487	$1,579	$3,929
Domestic (Israel) [Member]	'	'	'
Other Comprehensive Income (Loss), Tax [Abstract]	'	'	'
Net comprehensive loss (income) before taxes	10,505	1,579	3,929
Foreign (U.S) [Member]	'	'	'
Other Comprehensive Income (Loss), Tax [Abstract]	'	'	'
Net comprehensive loss (income) before taxes	($18)	$0	$0

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	26.50%	25.00%
Operating Loss Carryforwards	$10,241	'
Foreign Tax Authority [Member]	'	'
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	35.00%	'

CONTINGENT_LIABILITIES_AND_COM2

CONTINGENT LIABILITIES AND COMMITMENTS (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
2014	$122
2015	102
2016	73
Operating Leases, Future Minimum Payments, Due in Four and Five Years, Total	297
New Operating Lease Agreement [Member]	'
2014	48
2015	41
2016	22
Operating Leases, Future Minimum Payments, Due in Four and Five Years, Total	$111

CONTINGENT_LIABILITIES_AND_COM3

CONTINGENT LIABILITIES AND COMMITMENTS (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating Leases, Rent Expense, Net	$50	$44	$61
Revenue from Grants	106	'	'
Description of Grant Received	'up to 100% of the amount of grants received (100% plus interest at LIBOR).	'	'
Accrued Royalties	115	'	'
New Operating Lease Agreement [Member]	'	'	'
Operating Leases, Rent Expense, Net	$51	$18	$29
Office of Chief Scientist [Member] | Maximum [Member]	'	'	'
Royalties percentage	5.00%	'	'
Office of Chief Scientist [Member] | Minimum [Member]	'	'	'
Royalties percentage	3.00%	'	'

SHAREHOLDERS_EQUITY_DEFICIENCY2

SHAREHOLDERS' EQUITY (DEFICIENCY) (Details) (Employees and Directors [Member], USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Employees and Directors [Member]	'		'
Number of options, Outstanding at beginning of year	461,118		465,520
Number of options, Granted	552,890	[1]	0	[1]
Number of options, Exercised	-208,708		-2,471
Number of options, Forfeited	0		-1,931
Number of options, Outstanding at end of year	805,300		461,118
Number of options, Vested and expected to vest	805,300		461,118
Number of options, Options exercisable at the end of the period	308,909		366,464
Weighted average exercise price, Outstanding at beginning of year	$0.20		$0.21
Weighted average exercise price, Granted	$9.87	[1]	$0	[1]
Weighted average exercise price, Exercised	$0.14		$0.33
Weighted average exercise price, Forfeited	'		$0.33
Weighted average exercise price, Outstanding at end of year	$6.86		$0.20
Weighted average exercise price, Vested and expected to vest	$6.86		$0.20
Weighted average exercise price, Options exercisable at the end of the period	$0.33		$0.22
[1]	Including 22,388 and 102,275 options to purchase ordinary shares granted in May and December 2013 to a director and an employee, respectively. The exercise price is $ 8 and $ 17.6, respectively. The vesting of the options is subject to certain performance conditions. As of December 31, 2013, the performance conditions are probable and the Company recorded share based expenses in the amount of $ 109.

SHAREHOLDERS_EQUITY_DEFICIENCY3

SHAREHOLDERS' EQUITY (DEFICIENCY) (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013
Granted to Consultants on April 2, 2008 [Member]	'
Number of options	58,700
Exercise price	$0.00
Expiration date	2-Apr-18
Granted to Consultants on February 28, 2010 [Member]	'
Number of options	8,805
Exercise price	$2.18
Expiration date	28-Feb-20
Granted to Consultants on February 13, 2011 [Member]	'
Number of options	1,174
Exercise price	$0.00
Expiration date	13-Feb-21
Granted to Consultants on February 17, 2011 [Member]	'
Number of options	3,804
Exercise price	$0.00
Expiration date	17-Feb-21
Granted to Consultants [Member]	'
Number of options	72,483	[1]
[1]	All options were fully vested on grant date.

SHAREHOLDERS_EQUITY_DEFICIENCY4

SHAREHOLDERS' EQUITY (DEFICIENCY) (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013
Granted1 to Underwriters on May 28, 2013 [Member]	'
Number of options	52,083
Exercise price	$12
Expiration date	28-May-15
Granted2 to Underwriters on May 28, 2013 [Member]	'
Number of options	52,083
Exercise price	$16
Expiration date	28-Nov-15
Granted3 to Underwriters on May 28, 2013 [Member]	'
Number of options	52,084
Exercise price	$20
Expiration date	28-May-16
Granted3 to Underwriters [Member]	'
Number of options	156,250

SHAREHOLDERS_EQUITY_DEFICIENCY5

SHAREHOLDERS' EQUITY (DEFICIENCY) (Details 3) (USD $)	12 Months Ended				71 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012		Dec. 31, 2011	Dec. 31, 2013
Employee Benefits and Share-based Compensation, Total	$1,540	$26		$1,553	$3,759
Research and Development Expense [Member]	'	'		'	'
Employee Benefits and Share-based Compensation, Total	430	0	[1]	18	913
General and Administrative Expense [Member]	'	'		'	'
Employee Benefits and Share-based Compensation, Total	$1,110	$26		$1,535	$2,846
[1]	Represents an amount less than $ 1.

SHAREHOLDERS_EQUITY_DEFICIENCY6

SHAREHOLDERS' EQUITY (DEFICIENCY) (Details Textual) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

31-May-13

Dec. 31, 2013

Feb. 28, 2010

31-May-13

31-May-13

Oct. 31, 2013

31-May-13

Dec. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Recognized in 2014 [Member]

Recognized in 2015 [Member]

Incentive Option Plan 2010 [Member]

Incentive Option Plan 2010 [Member]

Incentive Option Plan 2010 [Member]

IPO [Member]

IPO [Member]

Secondary Public Offering [Member]

Secondary Public Offering [Member]

Secondary Public Offering [Member]

Maximum [Member]

Minimum [Member]

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

3,125,000

'

2,300,000

'

'

'

'

Stock Issued During Period, Value, New Issues

$21,920

'

'

'

'

'

'

'

'

'

'

$21,920

$35,334

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

'

'

'

123,553

'

'

'

'

'

Number of Warrants Exercised

'

'

'

'

'

'

'

'

120,255

'

'

'

'

'

'

Common Shares Issued, Warrants Exercised

'

'

'

'

'

'

'

'

85,192

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

372,725

1,693,047

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'8 years 2 months 8 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

'6 years 4 months 13 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

8,957

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value

5,459

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

'

'

'

1,921

603

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award

'

'

'

'

'

22,388

102,275

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased

'

'

'

'

'

$8

$17.60

'

'

'

'

'

'

'

'

Stockholders Equity Note, Stock Split

'4.87-to-one bonus shares (equivalent to a 5.87-for-1 stock split).

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

10,000,000

Allocated Share-based Compensation Expense

$841

$26

$1,394

'

'

'

$109

'

'

'

'

'

'

'

'

RELATED_PARTY_BALANCES_AND_TRA2

RELATED PARTY BALANCES AND TRANSACTIONS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Related Party Transaction [Line Items]	'		'		'
Convertible notes	$0	[1]	$610	[1]	'
Other accounts payable	47	[2],[3]	21	[2],[3]	'
Amounts charged to:	'		'		'
Research and development expenses	341	[3],[4],[5]	0	[3],[4],[5]	0	[3],[4],[5]
General and administrative expense	1,266	[2],[3],[4],[5],[6]	401	[2],[3],[4],[5],[6]	1,786	[2],[3],[4],[5],[6]
Financial expense	$0	[1],[5]	$60	[1],[5]	$0	[1],[5]
[1]	One of the Company's shareholders invested as part of the Company's issuance of the Convertible Notes.
[2]	An agreement was signed on June 2, 2011 between the Company and one its shareholders, as a contractor to render services related to pre-clinical, clinical, regulatory and intellectual property issues, for an amount of approximately $ 3 per month. During May 2013, the monthly fee was increased to an amount of $ 5. The amendment was effective upon consummation of the initial public offering in May 2013.
[3]	Under the employment agreement, dated March 4, 2010, with the Company's Chief Executive Officer and Director, and following a salary increase approved April 14, 2011, the CEO was entitled to a gross monthly salary of $ 14. During January 2013, the Company increased the monthly salary to an amount of $ 15 which became effective upon the Company's IPO. In June 2013, the Company granted the CEO a bonus in the amount of $ 75 in connection with the consummation of the IPO and in August 2013, the Company increased the bonus amount in $ 125, to a total of $ 200. (see also Note 12 (c)).
[4]	The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the company renders the Company with office services and office lease for a monthly fee in the amount of approximately $ 4 since June 1, 2010. Each party may terminate the agreement with 30-days' notice. The agreement was terminated in September 2013.
[5]	Including share based compensation expenses for the years ended December 31, 2013, 2012 and 2011, in the amounts of $ 841, $ 26 and $ 1,394, respectively.
[6]	On March 1, 2008, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, as a contractor to render management, finance and operation services. The Company pays the consultant an amount of $ 7 per month. During May 2013, the monthly fee was increased to an amount of $ 12. The amendment was effective upon consummation of the IPO in May 2013. In June 2013, and in connection to the consummation of the IPO, the Company granted the consultant a bonus in the amount of $50. (see also Note 12 (a)).

RELATED_PARTY_BALANCES_AND_TRA3

RELATED PARTY BALANCES AND TRANSACTIONS (Details Textual) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

In Thousands, unless otherwise specified

Jun. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

31-May-13

Jun. 30, 2011

31-May-13

Mar. 31, 2008

Jun. 30, 2013

Jan. 31, 2013

Apr. 30, 2011

Aug. 31, 2013

Jun. 30, 2013

Aug. 31, 2013

Pre Clinical, Clinical, Regulatory and Intellectual Property Issues [Member]

Pre Clinical, Clinical, Regulatory and Intellectual Property Issues [Member]

Consultant [Member]

Consultant [Member]

Consultant [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Deferred Bonus [Member]

Deferred Bonus [Member]

Deferred Bonus [Member]

Deferred Bonus [Member]

Maximum [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

$841

$26

$1,394

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense

4

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease Expiration Date

30-Sep-13

'

'

'

'

'

'

'

'

'

'

'

'

'

General Contractor Costs

'

'

'

'

5

3

12

7

'

'

'

'

'

'

Officers Compensation

'

'

'

'

'

'

'

'

'

15

14

'

'

'

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

'

'

'

'

'

'

'

'

$50

'

'

$125

$75

$200

FINANCIAL_EXPENSES_NET_Details

FINANCIAL EXPENSES, NET (Details) (USD $)	12 Months Ended			71 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Financial expenses:	'	'	'	'
Interest expense	$0	$3	$3	$23
Exchange rate	7	15	41	99
Bank fees	9	0	0	9
Interest on convertible notes	203	62	0	310
Interest Expense, Total	219	80	44	441
Financial income:	'	'	'	'
Interest income	22	2	21	48
Interest Income, Securities, Operating	22	2	21	48
Interest Income (Expense), Net, Total	$197	$78	$23	$393

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (Subsequent Event [Member], USD $)	Mar. 31, 2014	Feb. 28, 2014	Mar. 31, 2014	Feb. 28, 2014	Feb. 28, 2014
In Thousands, except Share data, unless otherwise specified	Two Employees [Member]	Chief Executive Officer [Member]	Board of Directors Chairman [Member]	Deferred Bonus [Member]	Deferred Bonus [Member]
				Chief Financial Officer [Member]	Chief Executive Officer [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	'	'	'	$200	$200
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	155,000	150,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	172,725	'	'